Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Myelodysplastic Syndromes 3Recurrence 1Primary Myelofibrosis 1Oligodendroglioma 1Myeloproliferative Disorders 1Leukemia, Myeloid, Acute 1Gliosarcoma 1Glioblastoma 1Ependymoma 1Brain Stem Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 53Bevacizumab 33Radiotherapy 27Radiation 12Erlotinib Hydrochloride 12Radiotherapy, Intensity-Modulated 8Radiotherapy, Conformal 8Irinotecan 6Vorinostat 5Sorafenib 5Sirolimus 5temsirolimus 4Magnetic Resonance Spectroscopy 4Immunoglobulin G 4Disulfides 4Carmustine 4veliparib 3plerixafor 3carmustine, poliferprosan 20 drug combination 3Radiosurgery 3Everolimus 3Dasatinib 3Bortezomib 3vandetanib 2tandutinib 2sargramostim 2poly ICLC 2pembrolizumab 2pazopanib 2ferric pyrophosphate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Gliosarcoma × GRN163L peptide × Clear all
NCT01836549 2018-07-20

Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors

Pediatric Brain Tumor Consortium

Phase 2 Terminated
43 enrolled 14 charts
CNSSarcoma

Astrocytoma, Ependymoma, Glioblastoma, Oligodendroglioma, Gliosarcoma, Brain Stem Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡